Comparative Pharmacology
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus PREVACID IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus PREVACID IV.
ASPRUZYO SPRINKLE vs PREVACID IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASPRUZYO SPRINKLE (lacosamide) enhances slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting repetitive neuronal firing.
Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of gastric parietal cells. This action is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion.
Oral: 30 mg once daily, with or without food. Sprinkle capsules can be opened and contents mixed with soft food or liquid.
30 mg intravenous infusion over 30 minutes once daily for up to 7 days; may switch to oral therapy when patient can tolerate oral intake.
None Documented
None Documented
Terminal half-life is approximately 20-30 hours, allowing for once-daily dosing. Steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 1.5–2 hours in healthy individuals; however, the pharmacodynamic half-life (duration of acid suppression) is longer (up to 24 hours) due to accumulation in parietal cell canaliculi.
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with <2% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of metabolites.
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 75% excreted in urine as metabolites, with less than 1% as unchanged drug; about 20% eliminated in feces via bile.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor